Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), GlaxoSmithKline ..... Horsemen": Regeneron ( REGN ), Gilead ( GILD ), Biogen Idec ( BIIB ) and Celgene ( CELG ). Sales of these four surpass
July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis,...
comments sent the Biotech Index and bellwethers like Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), and Gilead (NASDAQ ..... biotech names, not the large cap names. Clearly, Biogen Idec 's "valuation" is less of a concern given the
Biogen Idec Inc . (NASDAQ: BIIB ) Q2 2014 Earnings Conference Call July 23, 2014 09:00 ET Executives ..... today. At this time, I would like to welcome everyone to the Biogen Idec Q2 2014 Earnings Conference Call. All lines have been placed
lines and pipeline of Biogen Idec (NASDAQ: BIIB ). This is a company ..... too low here and that BIIB is probably headed for ..... ground. Introduction : Biogen Idec reported blowout numbers today: Biogen Idec Inc . today reported second
The European Commission approves Biogen Idec 's ( BIIB +11.2% ) Plegridy ( peginterferon beta-1a ) as a treatment ..... subcutaneous injection using a prefilled syringe. Plegridy is Biogen 's fifth product offering for MS. Post your comment!
July 23 (Reuters) - Biogen Idec Inc : * Says in an investor conference call that company does not think tax inversions are an adequate rationale for business
July 23 (Reuters) - Biogen Idec Inc : * Says EU has approved its Plegridy drug for multiple sclerosis. Medicine is a pegylated form of interferon given by injection once every two weeks.
Tecfidera's growth trajectory. Biogen leads the $15 billion ..... the merger, served as Biogen Idec 's CEO and president ..... prioritization, from which Biogen Idec could benefit. In addition ..... potential acquirers. Biogen Idec discovers, develops
Biogen Idec reported second-quarter results that were ..... That said, we believe that investors in Biogen at recent prices assume a strong hemophilia ..... competitors), and a high success rate for Biogen 's novel drug candidates (many of which